Hebang Biotech Announcement: In 2025, operating revenue was 7.1888 billion yuan, a year-on-year decrease of 15.91%. The net loss attributable to shareholders of the listed company was 536 million yuan; in the same period last year, the net profit was 31.4647 million yuan. The company plans its 2025 profit distribution as follows: no profit distribution and no capital increase via transfer of surplus reserves from the reserve fund.

K-LinePoet

2026-04-21 17:58:47

Hebang Biotech Announcement, 2025 operating revenue is 7.19B yuan, a year-on-year decrease of 15.91%. Net loss attributable to shareholders of the listed company is 536 million yuan, compared to a net profit of 31.4647 million yuan in the same period last year. The company plans that in 2025, there will be no profit distribution and no transfer of surplus reserves to increase share capital.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
297.7K Popularity
#
Gate13thAnniversaryLive
868.95K Popularity
#
BitcoinBouncesBack
171.88K Popularity
#
USIranTalksProgress
877.98K Popularity
#
HKUnveilsNewCryptoRules
274.36K Popularity

Sitemap

HeBang Biotech: Net loss of 536 million yuan in 2025

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

BitcoinBouncesBack

USIranTalksProgress

HKUnveilsNewCryptoRules

Pin